Peptide vaccine antigens are presented on HLA-DR of APCs to prime T cells; the resulting effector T cells kill tumor cells presenting the neoantigen peptides (primarily on HLA class I, sometimes class II). HLA-DRB1-expressing cells are not themselves targeted for killing.